

Veronika Matuskova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3979830/publications.pdf>

Version: 2024-02-01

7
papers

106
citations

1684188
5
h-index

1720034
7
g-index

9
all docs

9
docs citations

9
times ranked

109
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. <i>British Journal of Ophthalmology</i> , 2023, 107, 384-391.	3.9	15
2	Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2021, 139, 68.	2.5	50
3	Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-8.	1.3	4
4	An association of neovascular age-related macular degeneration with polymorphisms of CFH, ARMS2, HTRA1 and C3 genes in Czech population. <i>Acta Ophthalmologica</i> , 2020, 98, e691-e699.	1.1	10
5	Uveal melanoma - testing of abnormalities of chromosome 3 and 8 in the Czech Republic. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020, 164, 401-409.	0.6	0
6	Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. <i>Seminars in Ophthalmology</i> , 2018, 33, 690-699.	1.6	16
7	<i>CD36</i> gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy. <i>Ophthalmic Genetics</i> , 2018, 39, 4-10.	1.2	10